JP6236062B2 - 抗mif抗体とグルココルチコイドの併用療法 - Google Patents
抗mif抗体とグルココルチコイドの併用療法 Download PDFInfo
- Publication number
- JP6236062B2 JP6236062B2 JP2015506211A JP2015506211A JP6236062B2 JP 6236062 B2 JP6236062 B2 JP 6236062B2 JP 2015506211 A JP2015506211 A JP 2015506211A JP 2015506211 A JP2015506211 A JP 2015506211A JP 6236062 B2 JP6236062 B2 JP 6236062B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- mif
- glucocorticoid
- combination
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003862 glucocorticoid Substances 0.000 title claims description 137
- 238000002648 combination therapy Methods 0.000 title description 18
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 94
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 63
- 201000010099 disease Diseases 0.000 claims description 62
- 229960003957 dexamethasone Drugs 0.000 claims description 55
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 55
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 53
- 229960000890 hydrocortisone Drugs 0.000 claims description 47
- 238000011282 treatment Methods 0.000 claims description 34
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims description 23
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 19
- 201000008383 nephritis Diseases 0.000 claims description 15
- 208000010247 contact dermatitis Diseases 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 9
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 9
- 208000006673 asthma Diseases 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 230000007815 allergy Effects 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 claims description 3
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims description 2
- 208000031814 IgA Vasculitis Diseases 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 229940000425 combination drug Drugs 0.000 claims 2
- 230000003064 anti-oxidating effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 39
- 230000000694 effects Effects 0.000 description 36
- 230000027455 binding Effects 0.000 description 32
- 102000028677 Rab9 Human genes 0.000 description 28
- 108050007276 Rab9 Proteins 0.000 description 28
- 150000001413 amino acids Chemical class 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 26
- 102000028589 Rab4 Human genes 0.000 description 26
- 108010044923 rab4 GTP-Binding Proteins Proteins 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 25
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 24
- 101100328887 Caenorhabditis elegans col-34 gene Proteins 0.000 description 24
- 229960004436 budesonide Drugs 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 22
- 238000000034 method Methods 0.000 description 21
- 229960005205 prednisolone Drugs 0.000 description 21
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 18
- 150000003431 steroids Chemical class 0.000 description 18
- 241000282414 Homo sapiens Species 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 17
- 239000000427 antigen Substances 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 210000002540 macrophage Anatomy 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 13
- 201000001474 proteinuria Diseases 0.000 description 13
- 230000000699 topical effect Effects 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 229960004584 methylprednisolone Drugs 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000001434 glomerular Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 230000004110 gluconeogenesis Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 101000950847 Homo sapiens Macrophage migration inhibitory factor Proteins 0.000 description 7
- 101001011645 Homo sapiens Muellerian-inhibiting factor Proteins 0.000 description 7
- 101710119980 Macrophage migration inhibitory factor Proteins 0.000 description 7
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 7
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- -1 fluorocortron Chemical compound 0.000 description 7
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 description 7
- 102000057097 human MIF Human genes 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 208000027866 inflammatory disease Diseases 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000005499 meniscus Effects 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 206010014025 Ear swelling Diseases 0.000 description 5
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 5
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- AIXMJTYHQHQJLU-UHFFFAOYSA-N chembl210858 Chemical compound O1C(CC(=O)OC)CC(C=2C=CC(O)=CC=2)=N1 AIXMJTYHQHQJLU-UHFFFAOYSA-N 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 210000005069 ears Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 5
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 238000011706 wistar kyoto rat Methods 0.000 description 5
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 4
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 description 4
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 4
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 4
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 4
- 206010012442 Dermatitis contact Diseases 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102100034485 Ras-related protein Rab-2A Human genes 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 229960003728 ciclesonide Drugs 0.000 description 4
- 229960001146 clobetasone Drugs 0.000 description 4
- XXIFVOHLGBURIG-OZCCCYNHSA-N clobetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)CC2=O XXIFVOHLGBURIG-OZCCCYNHSA-N 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 229960004544 cortisone Drugs 0.000 description 4
- 229960003290 cortisone acetate Drugs 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 230000008175 fetal development Effects 0.000 description 4
- 229960000676 flunisolide Drugs 0.000 description 4
- 229960002714 fluticasone Drugs 0.000 description 4
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229960001664 mometasone Drugs 0.000 description 4
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 4
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 4
- 108010067765 rab2 GTP Binding protein Proteins 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 3
- 206010021263 IgA nephropathy Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 229940092705 beclomethasone Drugs 0.000 description 3
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 230000004797 therapeutic response Effects 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241001466804 Carnivora Species 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 108700011498 Glucocorticoid Receptor Deficiency Proteins 0.000 description 2
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 241001272720 Medialuna californiensis Species 0.000 description 2
- 244000062730 Melissa officinalis Species 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000004641 brain development Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 2
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 229960002011 fludrocortisone Drugs 0.000 description 2
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 108010009483 glucocorticoid receptor alpha Proteins 0.000 description 2
- 208000026352 glucocorticoid resistance Diseases 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 244000038280 herbivores Species 0.000 description 2
- 150000002402 hexoses Chemical class 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000002395 mineralocorticoid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000006208 topical dosage form Substances 0.000 description 2
- 229960005026 toremifene Drugs 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 230000035903 transrepression Effects 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- JLHMJWHSBYZWJJ-UHFFFAOYSA-N 1,2-thiazole 1-oxide Chemical compound O=S1C=CC=N1 JLHMJWHSBYZWJJ-UHFFFAOYSA-N 0.000 description 1
- WLKSPGHQGFFKGE-UHFFFAOYSA-N 1-chloropropan-2-yl n-(3-chlorophenyl)carbamate Chemical compound ClCC(C)OC(=O)NC1=CC=CC(Cl)=C1 WLKSPGHQGFFKGE-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- JYVLIDXNZAXMDK-UHFFFAOYSA-N 2-pentanol Substances CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010001382 Adrenal suppression Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010012205 Delayed puberty Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100023378 Homo sapiens MIF gene Proteins 0.000 description 1
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101150058224 MIF gene Proteins 0.000 description 1
- 101001018878 Mus musculus Macrophage migration inhibitory factor Proteins 0.000 description 1
- 206010028741 Nasal inflammation Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 101001018880 Rattus norvegicus Macrophage migration inhibitory factor Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000004732 Systemic Vasculitis Diseases 0.000 description 1
- 208000037913 T-cell disorder Diseases 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100023118 Transcription factor JunD Human genes 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- WKMYTPCPAWZWII-UHFFFAOYSA-N [2-(4-acetyloxyphenyl)-2-chloroethyl]-methylazanium;chloride Chemical compound Cl.CNCC(Cl)C1=CC=C(OC(C)=O)C=C1 WKMYTPCPAWZWII-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000005638 acute proliferative glomerulonephritis Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001659 chemokinetic effect Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000005637 crescentic glomerulonephritis Diseases 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940084953 dexamethasone 0.5 mg Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940039092 medicated shampoos Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940100661 nasal inhalant Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000018656 positive regulation of gluconeogenesis Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000003651 pro-proliferative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Description
・特に肝臓における糖新生の刺激。この経路は、非ヘキソース基質、例えばアミノ酸からのグルコース、およびトリグリセリド分解からのグリセロールの合成をもたらし、特に肉食動物およびある種の草食動物に重要である。糖新生に関与する酵素の発現の増強は、おそらくグルココルチコイドの最もよく知られた代謝機能である。
・肝外組織由来のアミノ酸の可動化。これは糖新生の基質として働く。
・筋肉および脂肪組織におけるグルコース摂取の阻害。脂肪分解により放出される脂肪酸は、筋肉などの組織のエネルギー産生に用いられ、放出されたグリセロールは、糖新生の別の基質を提供する。
・免疫抑制
・糖新生の増加、インスリン耐性、およびグルコーストレランス不全(「ステロイド糖尿病」)による高血糖症。
・皮膚脆弱性の増加、あざができやすい。
・腸カルシウム吸収の低下による負のカルシウムバランス。
・ステロイド性骨粗鬆症;骨密度の低下(骨粗鬆症、骨壊死、高い骨折リスク、遅い骨折修復)。
・内臓および体幹脂肪沈着(中心性肥満)および食欲増進による体重増加。
・副腎機能障害(長期使用し、漸減せずに突然中止した場合)
・筋肉分解(タンパク質分解)、脆弱;筋肉量および修復の減少。
・胸脂肪体の拡張および皮膚の小血管の拡張。
・無排卵、月経期間異常。
・成長障害、思春期遅延。
・血漿アミノ酸増加、尿形成増加;負の窒素バランス。
・中枢神経系に対する興奮作用(陶酔感、精神病)。
・頭蓋圧増加による緑内障。
・白内障
この目的は本発明により解決された。
・組換えMIF(ヒト、マウス、ラット、CHO、サル)の酸化還元調節(シスチン/GSSG介在の軽度の酸化)または組換えMIFのProclin300またはタンパク質架橋剤による処置は、Baxterの抗MIF抗体RAB9、RAB4およびRAB0の結合をもたらす。
・oxMIFの減少はAb結合の損失をもたらす。
・oxMIF異性体に対する特異性は、Abのin vivo生物学的効果と関連する。
・oxMIFレベルは疾患状態と関連しうる。
1. グルココルチコイド受容疾患の治療に用いるためのグルココルチコイドと組み合わせた抗MIF抗体。
2. グルココルチコイド受容疾患がグルココルチコイドによる治療に反応する1項に記載のグルココルチコイドと組み合わせた抗MIF抗体。
3. 炎症、アレルギー、癌、または喘息の治療に用いるための1または2項に記載のグルココルチコイドと組み合わせた抗MIF抗体。
4. 該抗体が抗oxMIF抗体である1、2、または3項に記載のグルココルチコイドと組み合わせた抗MIF抗体。
5. 抗MIF抗体が、下記群:抗MIF抗体RAB9、RAB4、RAB0、RAM9、RAM4、および/またはRAM0から選ばれる1〜4項のいずれかに記載の組み合わせ。
6. 該グルココルチコイドが、グルココルチコイドレセプターアゴニスト、例えば、メチルプレドニゾロン、プレドニゾロン、トリマシノロン、デキサメタゾン、パラメタゾン、フルオルコルトロン、ブデソニド、フルチカゾン、フルニソリド、シクレソニド、モメタゾン、クロベタゾン、コルチゾンおよびヒドロコルチゾン、および抗炎症性SEGRA’s/SEGRM’s(例えば、マプラコラート(=BOL303242X=ZK245186)、化合物A、RU24856、RU24782、RU40066、ZK 216348)からなる群から選ばれる1〜5項のいずれかに記載の組み合わせ。
7. 該抗MIF抗体が、抗体RAB9、RAB4、またはRAB0、またはRAM9、RAM4、またはRAM0、好ましくは抗体RAM9のいずれか1であり、該グルココルチコイドが、全身投与の場合は(メチル)プレドニゾロンおよびデキサメタゾンおよび局所投与の場合はブデソニドからなる群から選ばれ、該MIF関連疾患が、炎症、具体的には腎炎、さらにより好ましくはループス腎炎、糸球体腎炎、IgA、またはIgM腎症、全身性血管炎(例えば、結節性多発動脈炎、ウェゲナー肉芽腫症およびHenoch-Schoenlein紫斑病)、抗GBM腎炎および/または急速進行性糸球体腎炎、(タイプI、II、III、またはIV)、例えば、ANCA(抗好中球細胞質抗体)腎炎)である1〜6項のいずれかに記載の組み合わせ。
8. 該抗MIF抗体が、抗体RAB9、RAB4、またはRAB0、またはRAM9、RAM4、またはRAM0、好ましくは抗体RAM9のいずれかであり、該グルココルチコイドが、全身投与の場合は(メチル)プレドニゾロンおよびデキサメタゾンおよび局所投与の場合はブデソニドからなる群から選ばれ、該MIF関連疾患がループス腎炎である、1〜6項のいずれかに記載の組み合わせ。
9. 該抗MIF抗体が、抗体RAB9、RAB4、またはRAB0、またはRAM9、RAM4、またはRAM0、好ましくはRAM9のいずれかであり、該グルココルチコイドが、全身投与の場合は(メチル)プレドニゾロンおよびデキサメタゾンおよび局所投与の場合はブデソニドからなる群から選ばれ、該MIF関連疾患が全身性エリテマトーデスである、1〜6項のいずれかに記載の組み合わせ。
10. 抗MIF抗体が、抗体RAB9、RAB4、またはRAB0、またはRAM9、RAM4、またはRAM0、好ましくはRAM9のいずれかであり、該グルココルチコイドが、全身投与の場合はデキサメタゾンおよび(メチル)プレドニゾロンおよび局所投与の場合はブデソニドからなる群から選ばれ、該MIF関連疾患が皮膚の炎症である、1〜6項のいずれかに記載の組み合わせ。
11. 該抗MIF抗体が、抗体RAB9、RAB4、またはRAB0、またはRAM9、RAM4、またはRAM0、好ましくは RAM9のいずれかであり、該グルココルチコイドが、全身投与の場合はデキサメタゾンおよび(メチル)プレドニゾロンおよびブデソニド、または局所投与の場合はヒドロコルチゾンからなる群から選ばれ、該MIF関連疾患がT細胞性免疫反応により生じる、1〜6項のいずれかに記載の組み合わせ。
12. 該T細胞性免疫反応が、皮膚の炎症、例えば、乾癬、または接触性過敏症である10または11項の組み合わせ療法。
13. 該グルココルチコイドがブデソニドであり、該ブデソニドが局所適用のために製剤化される、10〜12項のいずれかの組み合わせ療法。
14. 該抗MIF抗体が、抗体RAB9、RAB4、またはRAB0、またはRAM9、RAM4、またはRAM0、好ましくは RAM9のいずれかであり、該グルココルチコイドがブデソニドであり、該MIF関連疾患が炎症性腸疾患(IBD)であり、該IBDが潰瘍性大腸炎およびクローン病から選ばれる1〜5項のいずれかに記載の組み合わせ療法。
15. 該抗MIF抗体が、抗体RAB9、RAB4、またはRAB0、またはRAM9、RAM4、またはRAM0、好ましくはRAM9のいずれかであり、該グルココルチコイドが、全身投与の場合は(メチル)プレドニゾロンおよびデキサメタゾンおよび局所投与の場合はブデソニドからなる群から選ばれ、該MIF関連疾患が多発性硬化症である、1〜6項のいずれかに記載の組み合わせ。
16. 1〜15項のいずれかに記載の組み合わせおよび使用説明書を含むキット。
17. グルココルチコイド受容疾患、具体的には、炎症、アレルギー、喘息、または癌の治療に用いるための上記1〜15のいずれかに記載の組み合わせまたは16項のキット。
RAM9(重鎖):E.coli GA.662-01.pRAM9hc - DSM 25860.
RAM4(軽鎖):E.coli GA.906-04.pRAM4lc - DSM 25861.
RAM9(軽鎖):E.coli GA.661-01.pRAM9lc - DSM 25859.
RAM4(重鎖):E.coli GA.657-02.pRAM4hc - DSM 25862.
RAM0(軽鎖):E.coli GA.906-01.pRAM0lc - DSM 25863.
RAM0(重鎖):E.coli GA.784-01.pRAM0hc - DSM 25864.
(発明の詳細な説明)
Biacoreによる抗体の特異的結合評価
ka=結合速度定数[M-1 s-1]
kd=解離速度定数[s-1]
KD=平衡解離定数=kd/ka [M]
DIQMTQSPSS LSASVGDRVT ITCRSSQRIM TYLNWYQQKP GKAPKLLIFV ASHSQSGVPS RFRGSGSETD FTLTISGLQP EDSATYYCQQ SFWTPLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC;
配列番号2、RAB4の軽鎖のアミノ酸配列:
DIQMTQSPGT LSLSPGERAT LSCRASQGVS SSSLAWYQQK PGQAPRLLIY GTSSRATGIP DRFSGSASGT DFTLTISRLQ PEDFAVYYCQ QYGRSLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC;
配列番号3、RAB0の軽鎖のアミノ酸配列:
DIQMTQSPGT LSLSPGERAT LSCRASQGVS SSSLAWYQQK PGQAPRLLIY GTSSRATGIP DRFSGSASGT DFTLTISRLQ PEDFAVYYCQ QYGRSLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC;
配列番号4、RAB2の軽鎖のアミノ酸配列:
DIQMTQSPVT LSLSPGERAT LSCRASQSVR SSYLAWYQQK PGQTPRLLIY GASNRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGNSLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC;
配列番号5、RAB9の重鎖のアミノ酸配列:
EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYSMNWVRQA PGKGLEWVSS
IGSSGGTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAGSQ
WLYGMDVWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYT
CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EFLGGPSVFL FPPKPKDTLM
ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV
VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP
PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG
SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLGK;
配列番号6、RAB4の重鎖のアミノ酸配列:
EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYAMDWVRQA PGKGLEWVSG
IVPSGGFTKY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVN
VIAVAGTGYY YYGMDVWGQG TTVTVSSAST KGPSVFPLAP CSRSTSESTA
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS
SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF
PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE
EQFNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP
REPQVYTLPP SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT
TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL
SLGK;
配列番号7、RAB0の重鎖のアミノ酸配列:
EVQLLESGGG LVQPGGSLRL SCAASGFTFS WYAMDWVRQA PGKGLEWVSG
IYPSGGRTKY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVN
VIAVAGTGYY YYGMDVWGQG TTVTVSSAST KGPSVFPLAP CSRSTSESTA
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS
SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF
PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE
EQFNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP
REPQVYTLPP SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT
TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL
SLGK;
配列番号8、RAB2の重鎖のアミノ酸配列:
EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYAMDWVRQA PGKGLEWVSG IVPSGGFTKY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVN VIAVAGTGYY YYGMDVWGQG TTVTVSSAST KGPSVFPLAP CSRSTSESTA
ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS
SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF
PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE
EQFNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP
REPQVYTLPP SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT
TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL
SLGK;
配列番号9、RAM0hcのアミノ酸配列:
EVQLLESGGG LVQPGGSLRL SCAASGFTFS WYAMDWVRQA PGKGLEWVSG IYPSGGRTKY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVN VIAVAGTGYY YYGMDVWGQG TTVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS
SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN
YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK;
配列番号10、RAM0lcのアミノ酸配列:
DIQMTQSPGT LSLSPGERAT LSCRASQGVS SSSLAWYQQK PGQAPRLLIY GTSSRATGIP DRFSGSASGT DFTLTISRLQ PEDFAVYYCQ QYGRSLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC;
配列番号11、RAM9hcのアミノ酸配列:
EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYSMNWVRQA PGKGLEWVSS IGSSGGTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAGSQ WLYGMDVWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK;
配列番号12、RAM9lcのアミノ酸配列:
DIQMTQSPSS LSASVGDRVT ITCRSSQRIM TYLNWYQQKP GKAPKLLIFV ASHSQSGVPS RFRGSGSETD FTLTISGLQP EDSATYYCQQ SFWTPLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC;
配列番号13、RAM4hcのアミノ酸配列:
EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYAMDWVRQA PGKGLEWVSG IVPSGGFTKY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVN VIAVAGTGYY YYGMDVWGQG TTVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK;
配列番号14、RAM4lcのアミノ酸配列:
DIQMTQSPGT LSLSPGERAT LSCRASQGVS SSSLAWYQQK PGQAPRLLIY GTSSRATGIP DRFSGSASGT DFTLTISRLQ PEDFAVYYCQ QYGRSLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC。
RAB4およびRAM4:aa 86〜102
RAB9およびRAM9:aa 50〜68
RAB0およびRAM0:aa 86〜102
RAB2:aa 86〜102
・特に肝臓における糖新生の刺激:この経路は、非ヘキソース基質(例えばアミノ酸)からのグルコースの、およびトリグリセリド分解からグリセロールの合成をもたらし、肉食動物およびある草食動物において特に重要である。糖新生に関与する酵素の発現の増強は、おそらくグルココルチコイドの最もよく知られた代謝機能である。
・肝臓外組織からのアミノ酸の移行:これらは糖新生の基質として働く。
・筋肉および脂肪組織におけるグルコース取り込み阻害:脂肪分解により放出された脂肪酸は、筋肉などの組織におけるエネルギーの生成に用いられ、放出されたグリセロールは、糖新生の別の基質を提供する。
ヒドロコルチゾン、酢酸コルチゾン、コルチゾン/コルチゾール、フルオロコルトロン、プレドニゾン、プレドニゾロン,メチルプレドニゾロン(特に全身投与用)、トリアムシノロン、デキサメタゾン、ベタメタゾン、パラメタゾン、ブデソニド(特に局所投与用)、SEGRAs(選択的グルココルチコイドレセプターアゴニスト)。
−RAM9とデキサメタゾンの組み合わせ、
−RAM9とブデソニドの組み合わせ、
−RAM9とヒドロコルチゾンの組み合わせ、
−RAM9とプレドニゾロンまたはメチルプレドニゾロンの組み合わせ、
−RAM0とデキサメタゾンの組み合わせ、
−RAM4とデキサメタゾンの組み合わせ、
−RAM0とブデソニドの組み合わせ、
−RAM4とブデソニドの組み合わせ、
−RAM0とプレドニゾロンまたはメチルプレドニゾロンの組み合わせ、
−RAM4とプレドニゾロンまたはメチルプレドニゾロンの組み合わせ、
−RAM4とヒドロコルチゾンの組み合わせ、
−RAM0とヒドロコルチゾン。
−腎炎、具体的には 糸球体腎炎、急速進行性糸球体腎炎(タイプI、II、III、またはIV)、全身性血管炎(例えば、結節性多発動脈炎、ウェゲナー肉芽腫症、Henoch-Schoenlein紫斑病、急性増殖性糸球体腎炎)
−ループス腎炎、ANCA腎炎、抗GBM腎炎(例えばグッドパスチャー病)、IgA腎症、IgM腎症
−エリテマトーデス
−T細胞性免疫反応、例えば、皮膚の炎症、例えば乾癬または接触性過敏症
−IBD、例えば潰瘍性大腸炎およびMorbusCrohn
−多発性硬化症
−リウマチ性関節炎
−ぶどう膜炎
−2型糖尿病
−気管支喘息
−接触性皮膚炎
−乾癬
−アトピー性皮膚炎
−膵炎
−天疱瘡
−シェーグレン病
−ベーチェット病
−Horton病
−強皮症
−多発筋炎。
表1.デキサメタゾン用量−ラット/マウス/ヒトでの比較
1) 500mgメチルプレドニゾロン/日、3日間(高用量);次いでプレドニゾロン最大30mg/日(低用量)を経口投与、または
2) プレドニゾロン最大60mg/日(中用量)を経口投与、次いで徐々に減量する(最大6カ月間かけることができる)。
(参考例)
A) 抗体スクリーニングのためのGCOアッセイ
B) IC 50 値を決定するためのアッセイ
C) 細胞増殖の阻害
D) 結合試験:抗MIF抗体のエピトープ決定
E) Biacoreによる抗MIF抗体のFab断片のアフィニティ測定
グルココルチコイド薬を用いる疾患の治療は、しばしば重度の副作用または用量増加の必要性により妨げられる。本発明において、本発明者らは、グルココルチコイド化合物(例えば、デキサメタゾン、ヒドロコルチゾン、またはプレドニゾロン)の有効性を抗oxMIF抗体との組み合わせにより増加させることができることを記載する。そのような組み合わせは、各単独療法に比べてそのような疾患の改善された療法をもたらし、患者の平均余命を有意に延長する可能性がある。
−低用量のグルココルチコイドで以前の高用量と同じ効果を達成し、副作用を減らすことができる。
−同じグルココルチコイド用量でより高い効果が得られる。
−高グルココルチコイド用量を必要であれば投与することができ、治療効果が増強される。
腎炎
実施例1:半月体形成性糸球体腎炎の動物モデル
抗MIF抗体の投与
実施例1a
・WKYラットに糸球体腎炎を誘導後4日に処置を行う。
・腎損傷の重症度を、一夜(第7日〜第8日)尿回収後および第8日に動物を処分後に評価する(図1参照)。
・0.25mg/kg デキサメタゾンの単回腹腔内注射は、タンパク尿を約50%(図2)、糸球体マクロファージ浸潤を約53%(図3)および半月体数を約25%(図5)減少させる。
→0.025mg/kgを準最適デキサメタゾン濃度として決定する。
→0.025mg/kgは、抗体RAM9の潜在的効果を試験するために適すると考えられる。
実施例1b
・WKYラットに糸球体腎炎を誘導後4および6日に処置を行う。
・腎損傷の重症度を、一夜(第7日〜第8日)尿回収後および第8日に動物を処分後に評価する(図5参照)。
・抗体RAM9の腹腔内注射は以下のものを減少させる:
−アルブミン尿(図6および図10):60mg/kg:約22%、120mg/kg:約25%。
−マクロファージ浸潤(図7および図11):60mg/kg:約26%、120mg/kg:約38%。
−半月体数(図8および図12):60mg/kg:約10%、120mg/kg:約12%。
・さらに、尿中MIF、TNFα、およびIl-1βは減少する。
実施例1c
・WKYラットに糸球体腎炎を誘導後4日(デキサメタゾン+抗体)および6日(抗体のみ)に処置を行う。
・腎損傷の重症度を、一夜(第7日〜第8日)尿回収後および第8日に動物を処分後に評価する(図9参照)。
・抗体RAM9およびデキサメタゾンの組み合わせは強い相乗効果を示す(図10〜12参照)。
−デキサメタゾンの効果は、明らかに>10倍強まる。
実施例2
実施例2a
「NZB/NZW F1ハイブリッドマウスにおけるデキサメタゾンの用量決定」
グループ1:ビークル
グループ2:デキサメタゾン 0.5mg/kg
グループ3:デキサメタゾン 1.0mg/kg
グループ4:デキサメタゾン 2.0mg/kg
グループ5:組織像コントロール
実施例2b
「NZB/NZW F1ハイブリッドマウスにおける抗MIF RAM9抗体と準最適デキサメタゾン用量の相乗作用」
「動物グループ」
グループ1:組織像コントロール
グループ2:コントロール抗体BAX C3
グループ3:抗MIF RAM9
グループ4:デキサメタゾン+コントロール抗体BAX C3
グループ5:デキサメタゾン+抗MIF RAM9
表2:実験2のまとめ
T細胞性疾患
実施例3a
T=0d:動物を感作する。
T=5d:抗炎症療法で処置し、マウスをチャレンジする。
T=6d:耳の腫脹を定量し、動物を塗擦し、耳をさらなる組織分析用に回収する。
実施例3b〜d:接触性過敏症
材料および方法
結果
結論
Claims (13)
- グルココルチコイド受容疾患の治療に使用するためのグルココルチコイドと抗マクロファージ遊走阻止因子(MIF)抗体とを含む組み合わせ医薬であって、該抗MIF抗体が、配列番号11で表されるアミノ酸配列からなる重鎖と、配列番号12で表されるアミノ酸配列からなる軽鎖との組み合わせからなる抗体であり、該グルココルチコイドが、デキサメタゾンまたはヒドロコルチゾンである、組み合わせ医薬。
- 該グルココルチコイド受容疾患がグルココルチコイドによる治療に反応する請求項1記載の組み合わせ医薬。
- 炎症、アレルギー、癌、または喘息の治療に使用するための請求項1または2記載の組み合わせ医薬。
- 該抗体が抗酸化MIF(oxMIF)抗体である、請求項1、2、または3記載の組み合わせ医薬。
- 該グルココルチコイド受容疾患が、ループス腎炎、糸球体腎炎、IgAまたはIgM腎症、結節性多発動脈炎、ウェゲナー肉芽腫症、Henoch-Schoenlein紫斑病、抗GBM腎炎、急速進行性糸球体腎炎(タイプI、II、III、またはIV)、または抗好中球細胞質抗体(ANCA)腎炎である、請求項1〜4のいずれかに記載の組み合わせ医薬。
- 該グルココルチコイド受容疾患がループス腎炎である請求項1〜4のいずれかに記載の組み合わせ医薬。
- 該グルココルチコイド受容疾患が全身性エリテマトーデスである、請求項1〜4のいずれかに記載の組み合わせ医薬。
- 該グルココルチコイド受容疾患が皮膚の炎症である、請求項1〜4のいずれかに記載の組み合わせ医薬。
- 該グルココルチコイド受容疾患がT細胞性免疫反応により生じる、請求項1〜4のいずれかに記載の組み合わせ医薬。
- T細胞性免疫反応が、乾癬または接触性過敏症である請求項9記載の組み合わせ医薬。
- 該グルココルチコイド受容疾患が炎症性腸疾患(IBD)であり、IBDが潰瘍性大腸炎およびクローン病からなる群から選ばれる請求項1〜4のいずれかに記載の組み合わせ医薬。
- 該グルココルチコイド受容疾患が多発性硬化症である、請求項1〜4のいずれかに記載の組み合わせ医薬。
- 請求項1〜12のいずれかに記載の組み合わせ医薬、および使用説明書を含むキット。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261624988P | 2012-04-16 | 2012-04-16 | |
US61/624,988 | 2012-04-16 | ||
US201261668864P | 2012-07-06 | 2012-07-06 | |
US61/668,864 | 2012-07-06 | ||
US201361785626P | 2013-03-14 | 2013-03-14 | |
US61/785,626 | 2013-03-14 | ||
PCT/EP2013/057892 WO2013156472A1 (en) | 2012-04-16 | 2013-04-16 | Combination therapy of anti-mif antibodies and glucocorticoids |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015514734A JP2015514734A (ja) | 2015-05-21 |
JP6236062B2 true JP6236062B2 (ja) | 2017-11-22 |
Family
ID=48190488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015506211A Active JP6236062B2 (ja) | 2012-04-16 | 2013-04-16 | 抗mif抗体とグルココルチコイドの併用療法 |
Country Status (17)
Country | Link |
---|---|
US (3) | US20150250873A1 (ja) |
EP (1) | EP2838559B1 (ja) |
JP (1) | JP6236062B2 (ja) |
KR (1) | KR20150008105A (ja) |
CN (1) | CN104470540B (ja) |
AU (2) | AU2013203957B9 (ja) |
CA (1) | CA2869987A1 (ja) |
CL (1) | CL2014002789A1 (ja) |
ES (1) | ES2779036T3 (ja) |
HK (1) | HK1206984A1 (ja) |
IL (1) | IL235037A0 (ja) |
MX (1) | MX2014012534A (ja) |
NZ (1) | NZ628454A (ja) |
PL (1) | PL2838559T3 (ja) |
RU (1) | RU2014145694A (ja) |
WO (1) | WO2013156472A1 (ja) |
ZA (1) | ZA201507929B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150029017A (ko) | 2012-07-10 | 2015-03-17 | 박스터 헬쓰케어 에스에이 | 항-mif 면역조직화학 |
WO2014047648A1 (en) | 2012-09-24 | 2014-03-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
WO2015106973A2 (en) * | 2014-01-03 | 2015-07-23 | Baxter Healthcare S.A. | Anti-mif immunohistochemistry |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
CA3098415A1 (en) * | 2018-06-07 | 2019-12-12 | Oncoone Research & Development Gmbh | Anti-oxmif/anti-cd3 antibody for cancer treatment |
US20230045873A1 (en) * | 2019-12-06 | 2023-02-16 | Oncoone Research & Development Gmbh | ANTI-oxMIF/ANTI-CD3 BISPECIFIC ANTIBODY CONSTRUCTS |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080407A (en) * | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
EP0702566B1 (en) * | 1993-05-17 | 2010-07-21 | Cytokine Pharmasciences, Inc | Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity |
US20030235584A1 (en) * | 2000-02-28 | 2003-12-25 | Kloetzer William S. | Method for preparing anti-MIF antibodies |
US7205107B2 (en) * | 2001-12-21 | 2007-04-17 | Cytokine Pharmasciences, Inc. | Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease |
JP2009529053A (ja) * | 2006-03-07 | 2009-08-13 | コンビナトアールエックス インコーポレーティッド | 免疫炎症性障害の処置のための組成物および方法 |
CN100457895C (zh) * | 2006-05-24 | 2009-02-04 | 中国科学院生物物理研究所 | 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用 |
TW200902027A (en) * | 2007-03-26 | 2009-01-16 | Combinatorx Inc | Compositions and methods for treating medical conditions |
RS53906B1 (en) * | 2008-01-04 | 2015-08-31 | Baxter International Inc. | ANTI MIF ANTITELA |
-
2013
- 2013-04-11 AU AU2013203957A patent/AU2013203957B9/en active Active
- 2013-04-16 NZ NZ628454A patent/NZ628454A/en unknown
- 2013-04-16 WO PCT/EP2013/057892 patent/WO2013156472A1/en active Application Filing
- 2013-04-16 CN CN201380028648.3A patent/CN104470540B/zh active Active
- 2013-04-16 US US14/394,709 patent/US20150250873A1/en not_active Abandoned
- 2013-04-16 CA CA2869987A patent/CA2869987A1/en active Pending
- 2013-04-16 EP EP13718822.3A patent/EP2838559B1/en active Active
- 2013-04-16 RU RU2014145694A patent/RU2014145694A/ru not_active Application Discontinuation
- 2013-04-16 ES ES13718822T patent/ES2779036T3/es active Active
- 2013-04-16 MX MX2014012534A patent/MX2014012534A/es unknown
- 2013-04-16 PL PL13718822T patent/PL2838559T3/pl unknown
- 2013-04-16 KR KR20147031758A patent/KR20150008105A/ko not_active Application Discontinuation
- 2013-04-16 JP JP2015506211A patent/JP6236062B2/ja active Active
-
2014
- 2014-10-07 IL IL235037A patent/IL235037A0/en unknown
- 2014-10-16 CL CL2014002789A patent/CL2014002789A1/es unknown
-
2015
- 2015-08-07 HK HK15107625.1A patent/HK1206984A1/xx unknown
- 2015-08-07 AU AU2015210447A patent/AU2015210447B2/en active Active
- 2015-10-26 ZA ZA2015/07929A patent/ZA201507929B/en unknown
-
2017
- 2017-11-01 US US15/801,260 patent/US20180280501A1/en not_active Abandoned
-
2020
- 2020-12-31 US US17/139,772 patent/US20210187105A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PL2838559T3 (pl) | 2020-06-01 |
IL235037A0 (en) | 2014-12-31 |
AU2015210447B2 (en) | 2016-10-20 |
CN104470540A (zh) | 2015-03-25 |
AU2013203957B2 (en) | 2015-09-03 |
AU2013203957A1 (en) | 2013-10-31 |
AU2013203957B9 (en) | 2015-10-15 |
CA2869987A1 (en) | 2013-10-24 |
RU2014145694A (ru) | 2016-06-10 |
NZ628454A (en) | 2015-10-30 |
US20150250873A1 (en) | 2015-09-10 |
EP2838559B1 (en) | 2019-11-27 |
ES2779036T3 (es) | 2020-08-13 |
JP2015514734A (ja) | 2015-05-21 |
US20180280501A1 (en) | 2018-10-04 |
MX2014012534A (es) | 2014-11-21 |
CL2014002789A1 (es) | 2014-12-12 |
CN104470540B (zh) | 2016-08-31 |
ZA201507929B (en) | 2017-11-29 |
AU2015210447A1 (en) | 2015-09-03 |
KR20150008105A (ko) | 2015-01-21 |
EP2838559A1 (en) | 2015-02-25 |
US20210187105A1 (en) | 2021-06-24 |
WO2013156472A1 (en) | 2013-10-24 |
HK1206984A1 (en) | 2016-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210187105A1 (en) | Combination therapy of anti-mif antibodies and glucocorticoids | |
US11530263B2 (en) | IL-18 binding protein (IL-18BP) in inflammatory diseases | |
KR102511343B1 (ko) | 염증성 질환에서 il-18 결합 단백질(il-18bp) 및 항체 | |
AU2013202693B2 (en) | Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics | |
US20180155419A1 (en) | Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras | |
EP3277718A1 (en) | Dosage regimen for anti-mif antibodies | |
US20170049885A1 (en) | Combination therapy of anti-mif antibodies and chemotherapeutics | |
WO2023235830A1 (en) | Method of treating vitiligo with interferon-gamma antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160217 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160331 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20160511 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160608 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20160615 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170619 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170829 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171027 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6236062 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |